Logo of The Journal of Bone & Joint Surgery (Br)
Quick search:        
          Advanced Search
Guest Access | Sign In
Journal of Bone and Joint Surgery - British Volume, Vol 88-B, Issue SUPP_II, 208.  
Copyright © 2006 by British Editorial Society of Bone and Joint Surgery
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jung, L.J
Right arrow Articles by Skopinska-Rozewska, E.S.R
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jung, L.J
Right arrow Articles by Skopinska-Rozewska, E.S.R

European Rheumatoid Arthritis Surgical Society


Pfäffikon, Switzerland – 25–27 May, 2006

President – Beat R. Simmen


S19 BENEFICIAL EFFECT OF ENOXAPARINE ON THE ANGIOGENIC ACTIVITY OF SERUM IN PATIENTS AFTER HIP SURGERY

JungL.J ; MaldykP.M ; SommerE.S ; WojciechowskaB.W ; Chorostowska-WynimkoJ.C.W ; BanyJ.B ; and Skopinska-RozewskaE.S.R

Warsaw

Angiogenesis, the growth of new blood vessels from pre-existing vasculature has an obvious and essential role in soft and hard tissue repair. During the wound healing many potential angiogenic factors are released and may be found in circulating blood. The most important are basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF).

Experimental data confirm the important role of VEGF and bFGF in wounds and bone healing. It was proved that heparin and its low-molecular derivatives may interfere with various steps of angiogenesis process. Enoxaparine (En) is frequently used as anticoagulant for prophylaxis of thromboembolic complications. The aim of this study was to evaluate in vivo angiogenic potency and VEGF and bFGF content of sera collected from 7 patients after hip surgery, treated for 14 days with 40 mg of En (Clexane, Aventis) daily. Evaluation of angiogenic activity was performed twice before surgery (before and 1 day after one En dose) and 14 days after surgery. Sera were injected intra-dermally to anaesthetized Bal/c mice and 72 hours later the number of newly-formed blood vessels was counted in dissecting microscope (SIA test). Cytokines concentration was estimated by ELISA. Results: Sera obtained after one En dose presented increase of angiogenic activity (57,3+/– 2,4, n=112, p<0.01)in comparison to the value before En (44.6 +/– 2.5, n=113 of newly-formed blood vessels. After 14 En doses, further increase was observed (72 +/– 4.9 blood vessels, n= 112).

BFGF levels increased after the first En dose, VEGF concentration was significantly higher after 14 injections as compare to the results obtained before or after one injection of En.

Conclusion: Beneficial effect of 14-days prophylaxis with enoxaparine on healing process might be expected in patients after hip surgery.

Correspondence should be addressed to ERASS Office, Schulthess Klinik, Lengghalde 2, CH-8008 ZURICH, Switzerland.






(c) British Editorial Society of Bone and Joint Surgery All Rights Reserved
Registered charity no: 209299     Print ISSN: 0301-620X
Hip, Knee, Trauma, Upper limb, Foot & Ankle, Paediatrics, Oncology, Spine, Arthroplasty, General